Business Context and Reporting Period
This Form 8-K filing by Medtronic Plc, dated May 2, 2016, reports a significant executive leadership transition. The filing details the departure of the Chief Financial Officer (CFO) and the appointment of a successor, effective June 20, 2016.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and employment terms.
Material Changes
- Departure of CFO: Gary L. Ellis notified the Company of his intent to transition out of the Executive Vice President and Chief Financial Officer role effective June 20, 2016. He will remain with the Company as Executive Vice President of Global Operations and Information Technology with no change to his compensation.
- Appointment of New CFO: Karen L. Parkhill was appointed as Executive Vice President and Chief Financial Officer, effective June 20, 2016. She joins from Comerica Incorporated, where she served as Vice Chairman and CFO since 2011.
Guidance, Outlook, and Compensation Details
The filing outlines the specific compensatory arrangements for the new CFO, Karen L. Parkhill, effective June 20, 2016:
- Base Salary: $750,000 annually.
- Annual Incentive (MIP): Target payout of 110% of base salary for fiscal year 2017.
- Long-Term Incentive Plan (LTIP): Aggregate target value of $3 million for fiscal year 2017, comprising:
- $1 million target annualized award under a performance plan.
- Stock option with a targeted grant date fair value of $1 million (vesting 25% annually).
- Restricted stock unit (RSU) with a targeted grant date value of $1 million (vesting 100% on the third anniversary subject to performance).
- Sign-on Compensation:
- $1 million cash bonus (50% payable within 30 days, 50% after 6 months).
- One-time New Hire RSU with a grant date value of $4.4 million, vesting in 33 1/3% increments subject to diluted EPS thresholds.
- Severance Provisions: In the event of termination without cause, Ms. Parkhill is entitled to two times the sum of her base salary and target annual cash incentive, 24 months of medical benefits, and continued vesting of the New Hire RSU. Change in Control provisions include a lump sum severance equal to three times the sum of base salary and the Highest Annual Bonus.
Investor Verification Checklist
- Verify the exact vesting schedules and performance thresholds for the $4.4 million New Hire RSU and the $3 million LTIP package.
- Review the full text of the Letter Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason" regarding severance eligibility.
- Confirm the impact of the $1 million cash bonus and $4.4 million RSU on the Company's immediate and future compensation expense.
- Monitor the transition timeline to ensure continuity of financial reporting and operations between June 20, 2016, and the effective date of the new CFO.